Eli Lilly Q4: Looking At Low Verzenio Sales And The Loxo Oncology Acquisition [Seeking Alpha]
LOXO ONCOLOGY (LOXO)
Last loxo oncology earnings: 11/8 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.loxooncology.com
Company Research
Source: Seeking Alpha
Eli Lilly Q4: Looking At Low Verzenio Sales And The Loxo Oncology Acquisition Summary Lilly's earnings fall in line with expectations, modest revenue beat from higher than anticipated performance in Mature Brands. Verzenio sales were much lower than expectations, reflecting competitive intensity in Metastatic Breast Cancer. Loxo Oncology brings some great assets at a high cost. Wall Street wants to know Lilly has a plan to maximize the sales potential of these assets. Lilly ( LLY PFE NVS What Happened to Verzenio? Verzenio is a CDK 4/6 inhibitor for HR+/HER2- Metastatic Breast Cancer. Verzenio competes with parity agents: Pfizer's IBRANCE and Novartis' KISQALI, for the same patient populations and market. Verzenio sales for Q4 2018 were $83 Million, about 20% below sales estimates of most Wall Street firms. Analysts probed on this further during the call's Q&A: "Verzenio was notably below our expectations. You mentioned buying patterns in the U.S. impacted this. Could you please quant
Show less
Read more
Impact Snapshot
Event Time:
LOXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LOXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LOXO alerts
High impacting LOXO ONCOLOGY news events
Weekly update
A roundup of the hottest topics